

FY2025 First Quarter

(Ended May 31, 2025)

Financial Briefing

July 11, 2025

RORZE CORPORATION

(Code : 6323)

<https://www.rorze.com/ir>

◆ Regarding forward-looking statements

The business forecasts and other forward-looking statements contained in this document are based on judgments made in accordance with information currently available for our company and do not constitute a guarantee or promise of the accuracy or completeness of such information. The forecast is also subject to change without notice due to changes in economic conditions, industry competition, markets and other systems.

◆ Data included in this document are stated as follows

JPY values : Rounded down to the nearest unit

Percentages : Rounded to the nearest unit after calculated in units of 1 JPY

Fiscal year : Refer to the "fiscal year ended February 28, 2026" as "FY2025" or "FY'25,"

Accounting period : The accounting periods of the consolidated, domestic companies and overseas subsidiaries are as follows:


	Q1 (1st Quarter)	Q2 (2nd Quarter)	Q3 (3rd Quarter)	Q4 (4th Quarter)	Full-year
Consolidated and domestic companies	Mar.~May.	Jun.~Aug.	Sep.~Nov.	Dec.~ The following Feb.	Mar.~ The following Feb.
Overseas subsidiaries	Jan.~Mar.	Apr.~Jun.	Jul.~Sep.	Oct.~Dec.	Jan.~Dec.

Company Profile


RORZE

Name	RORZE CORPORATION
Listed Market	Tokyo Stock Exchange Prime Market (Securities code : 6323)
Head Office	1588-2 Michinoue Kannabe-cho, Fukuyama-shi, Hiroshima
Establishment	March 30, 1985
Capital	982 million JPY
Business	Development, design, manufacturing, and sales of automation system for semiconductor/FPD production and life science automation products
Employees	Consolidated : 4,367 Non-consolidated : 256 (As of May 31, 2025)
Locations	Japan : Fukuyama, Yokohama, Kumamoto, Tsukuba and Tokyo Overseas : USA, Vietnam, Taiwan, Korea, Singapore, China and Germany


Global Network



Number of employees (consolidated)



- R&D, Manufacturing, Sales, Support
- Sales, Support
- R&D, Manufacturing
- Support



FY2025
First Quarter
(March 1 ~ May 31, 2025)
Consolidated Business Results

Summary of Q1 FY2025




- Quarterly Semi sales reached a record high, increasing equipment installation in Taiwan drove rapid sales growth
- Operating profit and ordinary profit declined with additional expenses by consolidating a subsidiary since last Q3
- US tariff policies have had no direct impact on the current business result

(Million JPY)

	FY'25 Q1	FY'24 Q1	YoY
Net sales	33,061	29,288	112.9%
Semi	28,230	26,836	105.2%
Analysis device ※	660	421	156.5%
FPD	1,001	262	382.3%
Life science	110	152	72.3%
Service/Parts etc. ※	3,058	1,615	189.3%
Operating profit	8,441	8,748	96.5%
Ordinary profit	7,241	11,361	63.7%
Profit attributable to owners of parent	5,263	8,774	60.0%
Average rate for the period (JPY/USD)	152	147	—

Quarterly Sales Trends




※ Part of the sales previously classified as “Service/Parts etc.” becomes included in “Analysis device” in FY'25 , and the figures for FY'24 have been revised accordingly.


Net sales by regions



- Semi Sales increased mainly for front-end process and advanced package to customers in Taiwan
- Semi Sales to end users increased, while those to equipment manufacturers decreased
- Impact of mutual tariffs by US was not significant on the current business performance and trades




“Net sales by region” is calculated based on the location of each customer’s head quarter



Operating profit

- SG&A expense increase in personnel costs and goodwill amortization as well as exchange rate impact offset upswing by sales increase mainly in Semi, resulting in a year-on-year decrease in operating profit




※ The impact of Nanoverse on consolidated operating profit (Million JPY) :
Labor Costs 469, R&D Expense 8, Goodwill amortization amount 719, Other SG&A Expense 304

Trends in orders, sales, and backlog



Semi

- Semi sales significantly increased QoQ to Taiwan, declining to major customers in USA and remaining high in China
- Order amount declined after more than trend increase in the previous quarter when solid demand for advanced package related equipment continued strong




Trends in orders, sales, and backlog



Analysis device

- Sales amount decreased after sales recorded upon concentrated acceptance in the previous quarter
- Order amount for wafer manufacturers steadily grew




※ Part of the sales previously classified as “Service/Parts etc.” becomes included in “Analysis device” in FY'25 , and the figures for FY'24 have been revised accordingly.

Trends in orders, sales, and backlog

FPD

- Sales declined following installation of large substrate transfer equipment in the previous quarter
- Order amount stayed at a level comparable to the sales volume in the current quarter




Consolidated balance sheet



- Inventory shifted to a 9% QoQ decline
- Cash and deposits have been retained primarily to facilitate business expansion, while a portion has been allocated to the repurchase of treasury shares


Assets


(Billion JPY)



Liabilities/Net assets

(Billion JPY)





FY2025 Business Forecast


Future Outlook for FY2025



- Semi for front-end process and advanced package related equipment to end-users will drive sales.
- Demand of equipment manufactures in USA and China will remain at a high level.
- Full-year profit level will remain flat. Production efficiency improvement will offset higher costs in the first half from a newly consolidated subsidiary in FY'24 Q3.

(Million JPY)

	FY'25 Q1 Achievements	FY'25 Q2 Forecast	Q2 Forecast Progress rate	FY'25 Full-year Forecast	Full-year Forecast Progress rate
Net Sales	33,061	63,711	51.9%	128,190	25.8%
Semi	28,230	53,338	52.9%	106,893	26.4%
Analysis device※	660	1,506	43.8%	4,163	15.9%
FPD	1,001	3,840	26.1%	6,550	15.3%
Life science	110	484	22.8%	1,590	6.9%
Service/Parts etc.※	3,058	4,541	67.4%	8,992	34.0%
Operating Profit	8,441	15,330	55.1%	30,345	27.8%
Ordinary Profit	7,241	15,397	47.0%	30,618	23.7%
Profit attributable to owners of parent	5,263	11,968	44.0%	23,499	22.4%




Topics

■ Total number of shares acquired (on the date of June 30, 2025)

- Total number of shares acquired 2,152,100 shares (40.6%)
- Total amount of share acquisition cost 3,471,924,469 yen (69.4%)

■ Reference

Class of shares	Common shares
Total number of shares that can be acquired	5,300,000 shares (3.0% of total number of issued shares (excluding treasury shares))
Total amount of share acquisition costs	Maximum of 5,000 million JPY
Acquisition period	From April 14, 2025 to July 31, 2025



References

RORZE

Unit



Atmospheric
Robot



Aligner



Load Port

System



EFEM



Vacuum Platform

System



Wafer Sorter



N2 Purge Wafer Stocker

Equipment
manufacturers(SPE)


Process equipment
Inspection equipment

End -user

Device manufacturers
Wafer manufacturers

Advanced packaging

Method for connecting chiplet to achieve higher device density and functionality expansion with a smaller footprint



Advanced packaging line



PLP EFEM



Tape Frame Sorter



Analysis device

RORZE

RORZE
RORZE IAS INC.




Semiconductor industry
SPEs
End-user
Device manufacturers
Wafer manufacturers


Other industry
Research institution
Environmental measuring
Instrument manufacturer
Chemical manufacturer etc.




RORZE SYSTEMS
(Subsidiary in Korea)



INDEX extra-large substrate transfer system




In-line returnable transfer system



Laser cutting equipment



Front-end :
FPD manufacturers
Glass for FPD
manufacturers



Display module equipment



Cell type extra-large packing equipment



Back-end :
FPD manufacturers



Incubator
SCALE48



CO₂ Incubator with medium exchange
function & cell imaging function
CellKeeper® II 48Plus



Mobile robot



Automatic medium
exchange system
CellFarm(L)-360™



Scheduling software
Green Button Go™ ※
(※Product of Biosero)



tissue staining and
gene function analysis



Drug discovery,
Regenerative
medicine
(universities,
pharmaceutical
companies)

RORZE